207 related articles for article (PubMed ID: 18656371)
1. In silico prediction of novel phosphodiesterase type-5 inhibitors derived from Sildenafil, Vardenafil and Tadalafil.
Antunes JE; Freitas MP; da Cunha EF; Ramalho TC; Rittner R
Bioorg Med Chem; 2008 Aug; 16(16):7599-606. PubMed ID: 18656371
[TBL] [Abstract][Full Text] [Related]
2. Critical amino acids in phosphodiesterase-5 catalytic site that provide for high-affinity interaction with cyclic guanosine monophosphate and inhibitors.
Zoraghi R; Francis SH; Corbin JD
Biochemistry; 2007 Nov; 46(47):13554-63. PubMed ID: 17979301
[TBL] [Abstract][Full Text] [Related]
3. Tadalafil and vardenafil.
Neumeyer K; Kirkpatrick P
Nat Rev Drug Discov; 2004 Apr; 3(4):295-6. PubMed ID: 15124623
[No Abstract] [Full Text] [Related]
4. Phosphodiesterase type V inhibitors: Occurrence and fate in wastewater and sewage sludge.
Nieto A; Peschka M; Borrull F; Pocurull E; Marcé RM; Knepper TP
Water Res; 2010 Mar; 44(5):1607-15. PubMed ID: 19959201
[TBL] [Abstract][Full Text] [Related]
5. 3D-QSAR studies on sildenafil analogues, selective phosphodiesterase 5 inhibitors.
Yoo J; Thai KM; Kim DK; Lee JY; Park HJ
Bioorg Med Chem Lett; 2007 Aug; 17(15):4271-4. PubMed ID: 17553682
[TBL] [Abstract][Full Text] [Related]
6. A 46-amino acid segment in phosphodiesterase-5 GAF-B domain provides for high vardenafil potency over sildenafil and tadalafil and is involved in phosphodiesterase-5 dimerization.
Blount MA; Zoraghi R; Ke H; Bessay EP; Corbin JD; Francis SH
Mol Pharmacol; 2006 Nov; 70(5):1822-31. PubMed ID: 16926278
[TBL] [Abstract][Full Text] [Related]
7. Binding of tritiated sildenafil, tadalafil, or vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation.
Blount MA; Beasley A; Zoraghi R; Sekhar KR; Bessay EP; Francis SH; Corbin JD
Mol Pharmacol; 2004 Jul; 66(1):144-52. PubMed ID: 15213306
[TBL] [Abstract][Full Text] [Related]
8. Comparative relaxing effects of sildenafil, vardenafil, and tadalafil in human corpus cavernosum: contribution of endogenous nitric oxide release.
Toque HA; Priviero FB; Teixeira CE; Claudino MA; Baracat JS; Fregonesi A; De Nucci G; Antunes E
Urology; 2009 Jul; 74(1):216-21. PubMed ID: 19371941
[TBL] [Abstract][Full Text] [Related]
9. Effects of phosphodiesterase inhibitors on tension induced by norepinephrine and accumulation of cyclic nucleotides in isolated human prostatic tissue.
Uckert S; Sormes M; Kedia G; Scheller F; Knapp WH; Jonas U; Stief CG
Urology; 2008 Mar; 71(3):526-30. PubMed ID: 18342202
[TBL] [Abstract][Full Text] [Related]
10. Bioactivities of a series of phosphodiesterase type 5 (PDE-5) inhibitors as modelled by MIA-QSAR.
Antunes JE; Freitas MP; Rittner R
Eur J Med Chem; 2008 Aug; 43(8):1632-8. PubMed ID: 18045743
[TBL] [Abstract][Full Text] [Related]
11. The molecular basis for the selectivity of tadalafil toward phosphodiesterase 5 and 6: a modeling study.
Huang YY; Li Z; Cai YH; Feng LJ; Wu Y; Li X; Luo HB
J Chem Inf Model; 2013 Nov; 53(11):3044-53. PubMed ID: 24180640
[TBL] [Abstract][Full Text] [Related]
12. Absence of clinically important HERG channel blockade by three compounds that inhibit phosphodiesterase 5--sildenafil, tadalafil, and vardenafil.
Dustan Sarazan R; Crumb WJ; Beasley CM; Emmick JT; Ferguson KM; Strnat CA; Sausen PJ
Eur J Pharmacol; 2004 Oct; 502(3):163-7. PubMed ID: 15476742
[TBL] [Abstract][Full Text] [Related]
13. Structure of the catalytic domain of human phosphodiesterase 5 with bound drug molecules.
Sung BJ; Hwang KY; Jeon YH; Lee JI; Heo YS; Kim JH; Moon J; Yoon JM; Hyun YL; Kim E; Eum SJ; Park SY; Lee JO; Lee TG; Ro S; Cho JM
Nature; 2003 Sep; 425(6953):98-102. PubMed ID: 12955149
[TBL] [Abstract][Full Text] [Related]
14. Towards a decade of detecting new analogues of sildenafil, tadalafil and vardenafil in food supplements: a history, analytical aspects and health risks.
Venhuis BJ; de Kaste D
J Pharm Biomed Anal; 2012 Oct; 69():196-208. PubMed ID: 22464558
[TBL] [Abstract][Full Text] [Related]
15. Identification of sildenafil, tadalafil and vardenafil by gas chromatography-mass spectrometry on short capillary column.
Man CN; Nor NM; Lajis R; Harn GL
J Chromatogr A; 2009 Nov; 1216(47):8426-30. PubMed ID: 19853256
[TBL] [Abstract][Full Text] [Related]
16. Drug Insight: oral phosphodiesterase type 5 inhibitors for erectile dysfunction.
Briganti A; Salonia A; Gallina A; Saccà A; Montorsi P; Rigatti P; Montorsi F
Nat Clin Pract Urol; 2005 May; 2(5):239-47. PubMed ID: 16474835
[TBL] [Abstract][Full Text] [Related]
17. Pre-clinical evidence for the use of phosphodiesterase-5 inhibitors for treating benign prostatic hyperplasia and lower urinary tract symptoms.
Tinel H; Stelte-Ludwig B; Hütter J; Sandner P
BJU Int; 2006 Dec; 98(6):1259-63. PubMed ID: 16956354
[TBL] [Abstract][Full Text] [Related]
18. High biochemical selectivity of tadalafil, sildenafil and vardenafil for human phosphodiesterase 5A1 (PDE5) over PDE11A4 suggests the absence of PDE11A4 cross-reaction in patients.
Weeks JL; Zoraghi R; Beasley A; Sekhar KR; Francis SH; Corbin JD
Int J Impot Res; 2005; 17(1):5-9. PubMed ID: 15538396
[TBL] [Abstract][Full Text] [Related]
19. Conversion of phosphodiesterase-5 (PDE5) catalytic site to higher affinity by PDE5 inhibitors.
Blount MA; Zoraghi R; Bessay EP; Beasley A; Francis SH; Corbin JD
J Pharmacol Exp Ther; 2007 Nov; 323(2):730-7. PubMed ID: 17690252
[TBL] [Abstract][Full Text] [Related]
20. Vardenafil: structural basis for higher potency over sildenafil in inhibiting cGMP-specific phosphodiesterase-5 (PDE5).
Corbin JD; Beasley A; Blount MA; Francis SH
Neurochem Int; 2004 Nov; 45(6):859-63. PubMed ID: 15312980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
